


**Indices**

	Last quote	1-day change	5-day change	1 month	1 year
<b>SOFIX</b>	462.89	-0.06%	-0.13%	2.43%	40.48%
<b>BG40</b>	155.64	-0.73%	-2.09%	1.97%	28.19%
<b>BGTR30</b>	330.66	0.01%	0.01%	0.86%	30.60%
<b>BGREIT</b>	87.35	-1.18%	-0.16%	0.38%	9.27%

**Market Trend**

**Market Capitalization in BGN**

Premium Equities Segment	1 426 785 899
Standard Equities Segment	5 792 868 915
Special Purpose Vehicles Segment	517 375 519
<b>Total</b>	<b>7 737 030 333</b>

**SOFIX components**

Stock	Last Price	Weekly Change	Bid	Ask
Advance Terrafund REIT	2.41	-0.82%	2.41	2.44
Albena	58.00	1.75%	56.50	58.00
Bulgaria Real Estate Fund REIT	0.54	-0.19%	0.54	0.54
Bulgartabac Holding	99.00	-5.71%	98.00	103.55
Central Cooperative Bank	1.00	1.01%	0.97	0.99
Chimimport	1.39	-1.77%	1.37	1.39
M+S Hydraulic	9.14	-0.65%	9.14	9.25
Eurohold Bulgaria	0.90	4.41%	0.87	0.90
First Investment Bank	2.27	0.62%	2.27	2.30
Industrial Holding Bulgaria	0.86	-1.26%	0.84	0.86
Monbat	6.30	-1.55%	6.30	6.39
Neochim	38.20	-4.38%	38.20	39.00
Sopharma	3.50	6.06%	3.45	3.51
Stara Planina Hold	2.96	-1.30%	2.96	3.00
Zarneni Hrani Bulgaria	0.40	-0.50%	0.40	0.41

**Sopharma is leading the market**

Bulgarian stocks were unchanged last week and the pressure on share prices was very low. The market's attention was grabbed by shares of Sopharma (3JR) and Chimimport (6C4). Both positions recorded higher volumes due to the buying interest and are good indicators for the positive bias of investors toward the local stocks, although domestic speculators are still cautious. Local buyers followed the larger volumes and managed to send the share of Sopharma 5% higher for the week to its highest level since August 2011. Moreover, the price is breaking on the upside its tight range during the last three months.

The most interesting event on the market was the big deal with rights for the convertible bond issue of Central Cooperative Bank (4CF). 72 million rights changed hands and this was the stake of Chimimport in the bank through its fully owned subsidiary CCB Group. The issue is EUR 36 million of 7-year bonds with 4.5% coupon. The conversion price is BGN 3.22 as compared to current stock price of BGN 0.99. CCB's equity-to-assets ratio is 0.10 and is below the average for the Bulgarian banking system. The stock is traded 10 times its profit and at low P/B of 0.3.

Biovet (53B) announced its consolidated report for the third quarter. The producer of veterinary medicines and food additives reported 35.5% increase of profit since the beginning of the year due to the better growth of sales /3.3%/ as compared to expenditures /0.93%/. However, the quarterly profit is lower by 8.3% on yearly basis. Biovet is traded at P/E ratio of 8.7 and has RoE of 8.5%. It is exporting 90% of its production that totaled BGN 134.4 million in 2013.

Advance Terrafund (6A6) announced its deals with agricultural land during October. The largest REIT sold 1 453 ha land last month. Revenues from sale of land since the beginning of 2013 were EUR 17.3 million. The sale of land increased substantially during the previous two months, which is probably due to the beginning of the new agricultural season and the completion of land concentration projects. Advance Terrafund is selling at average price per ha of EUR 5 496 this year, whereas the price for newly bought farmland was EUR 3 559 per ha. When comparing to the distributed dividends in 2012, the profit from sale of land until October could result to 10% dividend yield. The rental income from investment assets is 4.15% for the next 12 months.

**Disclaimer**

**Analyst Certification:** The research analyst(s) certifies that: (1) all of the views expressed in this document accurately reflect his or her personal views about any and all of the subject securities or issuers; (2) no part of any of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this document.

**Financial Interest:** ELANA Trading may trade or own shares of the analyzed companies. The research analyst(s) is not holding shares of the analyzed companies, unless otherwise noted.

**Regulatory Authority:** Financial Supervisory Commission, *Shar Planina* Street 33, 1303 Sofia, Bulgaria

**Information Disclosure:** All reasonable care has been taken to ensure the facts stated are accurate and opinions given are fair and reasonable. Our recommendations are based on information available to the public that we consider to be reliable but for the completeness and accuracy of which we assume no liability. Neither ELANA Trading, nor its directors, officers or employees shall in any way be responsible for its contents. The views expressed may differ from the views of other firm departments or representatives. Additional information is available upon request. Unless otherwise noted, sources for all information in charts and tables are ELANA Trading's calculations.

**Risks for Investors:** Information in this document should not be regarded as an offer to buy or sell any financial instruments. The investment possibilities discussed in this document may not be suitable for certain investors depending on their specific investment objectives and time horizon or in the context of their overall financial situation. In particular, the risks associated with an investment in the securities or the financial instruments under discussion are not explained in its entirety.

The prices or values of the securities may go down as well as up and can fluctuate and fall against the investor. The securities or investments may cause the investor to lose the amount invested. Past performance is not a guide to future performance. Changes in exchange rates may have an adverse effect on the value, price or income of the securities or investments.

**Valuation Methods:** Company valuations are based on the following methods: multiple-based (P/E, P/B, EV/EBITDA), historical valuation approaches, peer comparisons, discount models (DCF, DDM) or asset-based evaluation methods. Valuation models are dependent on macroeconomic factors, including interest rates, foreign exchange rates, prices of raw materials, and any expectations about the economy, the market sentiment. The valuation is based on expectations that might change rapidly and without notice, depending on developments specific to individual industries and countries. Recommendations and target prices derived from the models might therefore change accordingly. The application of models depends on forecasts of a range of economic variables, thus there is a range of reasonable variations within models. Any valuation is dependent upon inputs that are based on the subjective opinion of the analysts carrying out this valuation.

**Recommendations:** Analyst(s) recommendations are based on the specific factors for the company, sector, country and global developments, as compared to market indices. Recommendations and opinions reflect ELANA Trading's expectations over the 12-month period following publication from the perspective of long-only investment clients. ELANA Trading reserves the right to express different or contrary recommendations and opinions for different timescales or for other types of investment client. Except as otherwise noted, expected performance over next 12 months vary for different recommendations for Bulgarian stocks as follows:

<b>BUY</b>	More than 5% higher as compared to SOFIX and BG40 performance
<b>HOLD</b>	Market performance, +/-5% as compared to SOFIX and BG40
<b>SELL</b>	More than 5% lower as compared to SOFIX and BG40 performance

**Frequency of Recommendations:** No schedule of recommendations is available. The frequency of recommendations depends on specific factors to individual companies and the opinion of the analyst(s) for the necessity of minor or major changes.

**Copyrights:** The copyrights of ELANA Trading analyses belong to the Research Department of the brokerage and their content cannot be used for commercial purposes. Replication and redistribution of ELANA Trading analyses content is expressly prohibited without the prior written consent of the appointed contacts listed below.

**For more information, please contact:**

Research analyst  
Tsvetoslav Tsachev

Phone:  
+359 2 810 00 23

E-mail:  
[tsachev@elana.net](mailto:tsachev@elana.net)

Internet:  
[www.elana.net](http://www.elana.net)